The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen N-5021, Norway.
Br J Cancer. 2011 Jun 28;105(1):9-12. doi: 10.1038/bjc.2011.203. Epub 2011 Jun 14.
Glomeruloid microvascular proliferation (GMP), a novel histology-based angiogenesis marker, has been associated with decreased survival in several human cancers.
In this study, we evaluated the ability of GMP to predict clinical response to neoadjuvant chemotherapy in a series of locally advanced breast cancers (n=112).
Presence of GMP (21% of the cases) was significantly associated with high-grade tumours and TP53 mutations in addition to the basal-like and HER2 subtypes of breast cancer as defined by gene expression data. GMP was correlated to a gene expression signature for tumour hypoxia response. The GMP pattern was also significantly associated with lack of treatment response and progressive disease (P=0.004).
The findings suggest that GMP might be able to predict the lack of response to neoadjuvant chemotherapy in locally advanced breast cancer. Whether GMP may be an independent predictor compared with other factors including TP53 mutation status and tumour grade needs confirmation in larger studies.
肾小球样微血管增生 (GMP)，一种基于组织学的新型血管生成标志物，与多种人类癌症的生存率降低有关。
本研究中，我们评估了 GMP 在一系列局部晚期乳腺癌（n=112）中预测新辅助化疗临床反应的能力。
GMP 的存在（占病例的 21%）与高级别肿瘤以及基因表达数据定义的基底样和 HER2 型乳腺癌以外的 TP53 突变显著相关。GMP 与肿瘤缺氧反应的基因表达特征相关。GMP 模式也与缺乏治疗反应和进行性疾病显著相关（P=0.004）。
这些发现表明，GMP 可能能够预测局部晚期乳腺癌对新辅助化疗的无反应性。GMP 是否可以与其他因素（包括 TP53 突变状态和肿瘤分级）相比成为独立的预测因素，需要在更大的研究中得到证实。
